DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Arginine Therapy Shows Positive Impacts on Sickle Cell Disease in ASH 2022 Data
Individuals with sickle cell disease (SCD) present at the emergency department (ED) and are often admitted for hospitalization most commonly for vaso-occlusive pain episodes (VOEs). These episodes also referred to as “pain crises” due to the intense pain experienced by patients, cause an acute arginine (Arg) deficiency.
Arg supplementation has shown positive impacts on blood pressure, and cardiopulmonary function, and has decreased the length of patient’s hospital stay. With supplementation, patients often require lower doses of opioids to manage the episode.
Previous research demonstrated intravenous (IV) Arg improves mitochondrial (Mito) function. Beyond this, not much is understood about the precise mechanisms that enable Arg to mediate such benefits in this patient population.
Related Content
-
Community CenterMy Story With Sickle Cell Disease – CortneyMy name is Cortney and I was diagnosed w...
-
videos & visuals2017 April 29 SiNERGe Webinar on Bone Marrow Transplantshttps://www.youtube.com/watch?v=HudIvtS_...
-
people & placesJohn T. Horan MD, MPHJohn T. Horan, MD, MPH, is Associate Pro...
-
news & eventsEmmaus Life Sciences, Inc. to present results of phase 3 study of endariTM (L-glutamine oral powder) at 59th America...Emmaus will present results of a Phase 3...
-
videos & visualsSickle Cell Disease & Hospitalizationhttps://www.youtube.com/watch?v=G_P4Uc9w...
-
videos & visualsHydroxyurea and Sickle Cell Disease: A HRSA EMBRACE Projecthttps://www.youtube.com/watch?v=AyMP3P9E...
-
news & eventsRARE Patient Advocacy SummitEach year, Global Genes convenes one of ...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.